1
|
Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
|
Science
|
2004
|
5.31
|
2
|
Antigenic conservation and immunogenicity of the HIV coreceptor binding site.
|
J Exp Med
|
2005
|
4.68
|
3
|
HIV vaccine research: the way forward.
|
Science
|
2008
|
3.86
|
4
|
Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.
|
J Virol
|
2002
|
3.47
|
5
|
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
|
N Engl J Med
|
2012
|
3.15
|
6
|
An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum.
|
J Virol
|
2011
|
2.60
|
7
|
Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure.
|
PLoS Pathog
|
2010
|
2.55
|
8
|
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR.
|
J Virol
|
2003
|
2.42
|
9
|
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.
|
J Virol
|
2002
|
2.23
|
10
|
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses.
|
Cytometry A
|
2011
|
2.14
|
11
|
Characterization of neutralizing antibodies to West Nile virus.
|
Virology
|
2005
|
1.81
|
12
|
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.
|
J Virol
|
2005
|
1.76
|
13
|
Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.
|
Blood
|
2010
|
1.72
|
14
|
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
|
PLoS Pathog
|
2007
|
1.55
|
15
|
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
|
PLoS Pathog
|
2011
|
1.50
|
16
|
Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.
|
J Virol
|
2008
|
1.44
|
17
|
Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
|
J Virol
|
2012
|
1.44
|
18
|
A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope protein.
|
Mol Biol Cell
|
2006
|
1.38
|
19
|
DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets.
|
J Virol
|
2006
|
1.31
|
20
|
Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
|
J Virol
|
2009
|
1.26
|
21
|
Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.
|
Virology
|
2008
|
1.26
|
22
|
Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.
|
J Virol
|
2009
|
1.24
|
23
|
Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.
|
J Virol
|
2011
|
1.18
|
24
|
Effects of partial deletions within the human immunodeficiency virus type 1 V3 loop on coreceptor tropism and sensitivity to entry inhibitors.
|
J Virol
|
2007
|
1.09
|
25
|
Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities.
|
J Virol
|
2013
|
1.04
|
26
|
Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor.
|
J Virol
|
2009
|
1.03
|
27
|
Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.
|
Retrovirology
|
2013
|
0.99
|
28
|
Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
|
J Virol
|
2007
|
0.97
|
29
|
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.
|
J Virol
|
2009
|
0.96
|
30
|
Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins.
|
J Virol
|
2003
|
0.95
|
31
|
Structure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.
|
ACS Chem Biol
|
2011
|
0.94
|
32
|
Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses.
|
Blood
|
2006
|
0.90
|
33
|
Loss of a tyrosine-dependent trafficking motif in the simian immunodeficiency virus envelope cytoplasmic tail spares mucosal CD4 cells but does not prevent disease progression.
|
J Virol
|
2012
|
0.88
|
34
|
Simian immunodeficiency virus (SIV)/immunoglobulin G immune complexes in SIV-infected macaques block detection of CD16 but not cytolytic activity of natural killer cells.
|
Clin Vaccine Immunol
|
2006
|
0.88
|
35
|
Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complex.
|
J Biol Chem
|
2002
|
0.87
|
36
|
CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.
|
J Virol
|
2013
|
0.83
|
37
|
Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.
|
J Virol
|
2010
|
0.82
|
38
|
Trophoblasts are productively infected by CD4-independent isolate of HIV type 1.
|
AIDS Res Hum Retroviruses
|
2002
|
0.82
|
39
|
Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.
|
J Virol
|
2005
|
0.80
|
40
|
A single amino acid mutation in the envelope cytoplasmic tail restores the ability of an attenuated simian immunodeficiency virus mutant to deplete mucosal CD4+ T cells.
|
J Virol
|
2013
|
0.76
|
41
|
Modification of a viral envelope glycoprotein cell-cell fusion assay by utilizing plasmid encoded bacteriophage RNA polymerase.
|
J Virol Methods
|
2005
|
0.76
|
42
|
CCR5 mimicry by sulfated human anti-HIV-1 antibodies.
|
Cell
|
2003
|
0.76
|
43
|
Translating social and behavioral science research to the AIDS epidemic: a center for AIDS research perspective.
|
J Acquir Immune Defic Syndr
|
2013
|
0.75
|
44
|
A plea for justice for jailed medical workers.
|
Science
|
2006
|
0.75
|